经导管主动脉瓣置换术（TAVR）术前、术中和术后的抗栓治疗。

Antithrombotic therapy before, during and after transcatheter aortic valve replacement (TAVR).

作者信息

Sharma Abhishek, Goel Sunny, Lavie Carl J, Arbab-Zadeh Armin, Mukherjee Debabrata, Lazar Jason

机构信息

Division of Cardiovascular Medicine, State University of New York Downstate Medical Center, 1016, 50th Street, Apt 2C, Brooklyn, NY, 11219-9997, USA,

出版信息

J Thromb Thrombolysis. 2015 May;39(4):467-73. doi: 10.1007/s11239-014-1118-x.

DOI:10.1007/s11239-014-1118-x

PMID:25103613

Abstract

Transcatheter aortic valve replacement (TAVR) has been emerged as a promising alternative for the management of patients with severe AS who otherwise are deemed inappropriate candidates for surgery. Post procedural thromboembolic events and risk of bleeding continue to be a significant challenge in managing patients who underwent TAVR. This article systematically reviews the evidence, current guidelines and upcoming studies investigating antithrombotic therapy before, during and after TAVR.

摘要

经导管主动脉瓣置换术（TAVR）已成为治疗严重主动脉瓣狭窄（AS）患者的一种有前景的替代方法，这些患者原本被认为不适合进行手术。术后血栓栓塞事件和出血风险仍然是管理接受TAVR治疗患者的重大挑战。本文系统回顾了关于TAVR术前、术中和术后抗栓治疗的证据、现行指南及即将开展的研究。